文献速递泌尿生殖技术与安全PETCT

术前18F-FDG PET/CT肿瘤与肝脏标准化摄取值比值(TLR)升高预测透明细胞肾细胞癌根治性肾切除术后不良预后

Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative 18F-FDG PET/CT predicts poor prognosis of patients with clear cell renal cell carcinoma after nephrectomy.
PubMed 文献 · Eur J Radiol · 2020-08-15

回顾性分析69例术前接受18F-FDG PET/CT的新诊断透明细胞肾细胞癌患者,评估代谢参数SUVmax和肿瘤与肝脏比值(TLR)对肾切除术后无病生存的预测价值。多因素分析显示TLR(P=0.007,HR:5.489,95%CI:1.605-18.774)和pTNM分期(P=0.024,HR:10.385,95%CI:1.361-79.238)为DFS的独立预后预测因子;TLR正常者仅3例(8.3%)出现疾病进展,而TLR升高者22例(66.7%)出现疾病进展。

要点

  • 术前18F-FDG PET/CT的TLR>1.66是ccRCC肾切除术后DFS的独立预后预测因子。
  • TLR升高组疾病进展比例(66.7%)明显高于TLR正常组(8.3%)。
  • pTNM分期Ⅲ/Ⅳ亦为DFS独立预测因子(HR:10.385)。

核心结论

  • 术前TLR>1.66且pTNM分期高(Ⅲ/Ⅳ)的ccRCC患者肾切除术后生存结局显著不良,应密切监测以尽早发现疾病进展可能。

研究设计与样本

  • 回顾性研究,纳入69例新诊断ccRCC且术前接受18F-FDG PET/CT的患者,获取SUVmax和TLR代谢参数及WHO/ISUP分级、pTNM分期、静脉瘤栓等临床病理特征,采用单因素和多因素Cox比例风险分析筛选DFS预后因素。

关键影像表现/征象

  • 原文未报告具体影像征象,仅报告代谢参数SUVmax和TLR。

诊断标准与关键数值

  • TLR>1.66为DFS的独立预后预测因子(多因素P=0.007,HR:5.489,95%CI:1.605-18.774)。
  • pTNM分期Ⅲ/Ⅳ为DFS的独立预后预测因子(多因素P=0.024,HR:10.385,95%CI:1.361-79.238)。
  • 单因素分析中肿瘤大小>4.85 cm、pTNMⅢ/Ⅳ、WHO/ISUP G3/4、静脉瘤栓、辅助治疗、SUVmax>3.55、TLR>1.66与DFS降低相关(P<0.05)。

临床应用与阅片要点

  • 术前18F-FDG PET/CT测量TLR>1.66提示ccRCC肾切除术后疾病进展风险较高,作者建议密切监测以尽早发现疾病进展可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To assess the potential of using preoperative 18F-FDG PET/CT to predict the prognosis of patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy.

METHODS: Sixty-nine patients with newly diagnosed ccRCC who underwent 18F-FDG PET/CT prior to surgery were retrospectively reviewed. The metabolic parameters of maximum standardized uptake value (SUVmax) and tumor-to-liver ratio (TLR) from 18F-FDG PET/CT were obtained. Clinicopathological characteristics, including the World Health Organization/the International Society of Urological Pathology (WHO/ISUP) grade, pathological tumor node metastasis (pTNM) stage, venous tumor thrombus, and so on, were acquired. Univariate and multivariate Cox proportional hazards analyses were performed to identify the prognostic factors for disease-free survival (DFS).

RESULTS: Of the 69 patients, 25 patients (36.2%) experienced disease progression during the follow-up period. In univariate analysis, the primary tumor size (>4.85 cm), pTNM stage (Ⅲ/Ⅳ), WHO/ISUP grade (G3/4), venous tumor thrombus, adjuvant therapy, SUVmax (>3.55), and TLR (>1.66) were found to correlate with the incidence of decreased DFS (P < 0.05). In multivariate analysis, TLR (P = 0.007, HR: 5.489, 95%CI: 1.605-18.774) and pTNM stage (P = 0.024, HR: 10.385, 95%CI: 1.361-79.238) were revealed to serve as independent prognostic predictors for DFS after adjustment for other variables. Only 3 cases (8.3%) with normal TLR showed disease progression, while 22 cases (66.7%) with elevated TLR experienced disease progression.

CONCLUSION: ccRCC patients with preoperatively elevated TLR (>1.66) and high pTNM stages (Ⅲ/Ⅳ) had significantly unfavorable survival outcomes. These patients should be carefully monitored to detect the possibility of disease progression after nephrectomy as early as possible.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wu C, Cui Y, Zhao Y, et al. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative 18F-FDG PET/CT predicts poor prognosis of patients with clear cell renal cell carcinoma after nephrectomy. Eur J Radiol. 2020. PMID: 32882538. doi:10.1016/j.ejrad.2020.109218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。